The implementation of standardized antifungal testing methods for Candida spp. and Cryptococcus spp. (1, 2) and the recent development of testing methods for the filamentous fungi (3, 4) have facilitated the generation of meaningful data to detect and assess resistance to the current clinical armamentarium of antifungal agents. The use of these methods in global longitudinal surveillance programs has been useful in detecting emerging, rarely encountered yeast or mold organisms displaying decreased susceptibility to contemporary antifungal compounds (12, 16) and for monitoring the distribution of yeast and mold species with innate resistance profiles.
We summarize here the results of the global SENTRY Antimicrobial Surveillance Program (2006 to 2007) comparing the activities of eight currently marketed antifungal agents tested against clinical isolates from North America, Europe, Latin America, and the Asia-Pacific (APAC) region, with susceptibilities interpreted by using established CLSI breakpoint criteria, where available (1, 3) .
The collection of yeasts included Candida albicans (771 isolates), C. parapsilosis (238 isolates), C. glabrata (202 isolates), C. tropicalis (157 isolates), C. krusei (29 isolates), C. lusitaniae (14 isolates), C. guilliermondii (9 isolates), C. dubliniensis (7 isolates), C. famata (6 isolates), C. kefyr (5 isolates), and C. pelliculosa (4 isolates). The collection also included C. neoformans (33 isolates), and of the 61 molds, only Aspergillus fumigatus (49 isolates) is represented. All yeast and mold isolates were identified at the participating medical centers by the established methods in use at each institution. Isolates were requested to be from bloodstream infections, taken in consecutive order, and limited to one isolate per patient. The rates of occurrence in participating laboratories could then be detected by a prevalence mode. Confirmation of species identification was performed at the central reference laboratory by using Vitek (bioMérieux, St. Louis, MO) and by conventional reference methods (5, 17) .
Anidulafungin (4, 6, 7, 9, 10, 12, 14 (1, 3) . The final concentration ranges were as follows: anidulafungin, 0.001 to 32 g/ml; caspofungin, 0.008 to 16 g/ml; amphotericin B, 0.12 to 8 g/ml; 5-FC, 0.5 to 64 g/ml; fluconazole, 0.5 to 64 g/ml; itraconazole, 0.015 to 2 g/ml; posaconazole, 0.06 to 8 g/ml; voriconazole, 0.06 to 8 g/ml. The dilution scheme was selected to maximize capture of the MIC 50 (MIC for 50% of the strains tested) and MIC 90 for wild-type and resistant mutant populations and varied by agent. Further, the ranges of newer or investigational agents were expanded in order to identify populations resistant to these newer agents. Micafungin powder was not yet available from the manufacturer at the commencement of testing. The absence of micafungin in comparison with the other available echinocandins is a limitation of this study.
Broth microdilution testing for yeasts followed standardized procedures described in the CLSI M27-A3 reference method (1, 2) . All of the filamentous fungi were tested under conditions described for the CLSI M38-A2 reference method (3, 4) . Quality control isolates C. krusei ATCC 6258, C. parapsilosis ATCC 22019, and C. tropicalis ATCC 750 from the American Type Culture Collection were used as recommended (CLSI), and all results were observed within previously published ranges (1-3, 4, 7) . All panels were incubated in enclosed, humid containers at 35°C and visualized with a reading mirror at 24 h (echinocandins) and Mold testing panels were aerobically incubated at 35°C in an enclosed container and visualized with a reading mirror at 24 h (echinocandins) and 48 h (all other agents) under a biosafety hood. MICs of amphotericin B, itraconazole, posaconazole, and voriconazole were determined as the concentration at which no discernible growth was detected. MICs of 5-FC were determined as the lowest concentration at which a prominent decrease in growth (Ն50%) was visualized compared to the growth control (3, 4). As described for anidulafungin (10) and caspofungin (11), minimal effective concentrations (MECs) were determined as the lowest concentration at which a pronounced morphological change from filamentous growth to nonfilamentous growth was observed.
The A. fumigatus was the most common (80.3%) of the Aspergillus spp. tested ( Table 2 ). The agents most active against Aspergillus spp. included anidulafungin (MEC 90 , 0.008 g/ml), caspofungin (MEC 90 , 0.12 g/ml), and posaconazole (MIC 90 , 0.5 g/ml).
An analysis of Candida species by continent of origin is summarized in Table 3 (APAC region data not shown). Among the four most common Candida species reported, those from North America and Europe had the same rank order (C. albicans Ͼ C. glabrata Ͼ C. parapsilosis Ͼ C. tropicalis), which represents a shift in European species distribution from that in the previous SENTRY Program report (8, 9, 13) . C. glabrata rose in prevalence rank from third to second in Europe, and the C. parapsilosis rank order dropped to third. The impact of the more frequent occurrence of C. glabrata in Europe has yet to be clarified, and further longitudinal surveillance to detect sustained trends in species distribution and antifungal susceptibility appears warranted. Shifts in species distribution were also observed in Latin America and the APAC region, where the 2006 to 2007 rank order of Candida spp. was C. albicans Ͼ C. tropicalis Ͼ C. parapsilosis Ͼ C. glabrata. Among the 19 Candida isolates from the APAC region, no more than 8 were of one species (C. albicans). These yeasts had susceptibility rates ranging from 73.7% (itraconazole) to 100% (anidulafungin, caspofungin, amphotericin B, 5-FC).
This report extends the longitudinal global surveillance results for yeast and mold species collected from bloodstream and sterile body site infections and closely monitors developments in species occurrences with antifungal susceptibility processed by established CLSI reference methods (1-3, 4, 15) . As the use of routine antifungal testing by commercial or reference procedures remains a practice performed by a distinct minority of clinical laboratories (15) , the use of national or global antifungal surveillance networks clearly is a necessity to guide formulary choices (8, 9, 12, 13, 16) .
